Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

NCT04502966 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

199

Enrollment

NIH

Sponsor class

Conditions

Allergic Rhinoconjunctivitis
Grass Pollen Allergy

Interventions

BIOLOGICAL: Dupixent®
BIOLOGICAL: Grazax®
DRUG: Dupixent® Placebo
DRUG: Grazax® Placebo

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]